Coherus Oncology, Inc. (CHRS)
| Market Cap | 231.37M |
| Revenue (ttm) | 46.88M |
| Net Income (ttm) | 186.27M |
| Shares Out | 154.25M |
| EPS (ttm) | 1.52 |
| PE Ratio | 1.24 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,460,508 |
| Open | 1.480 |
| Previous Close | 1.480 |
| Day's Range | 1.460 - 1.525 |
| 52-Week Range | 0.720 - 2.616 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | 7.80 (+420.0%) |
| Earnings Date | Aug 6, 2026 |
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo... [Read more]
Financial Performance
In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $7.8, which is an increase of 420.00% from the latest price.
News
Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study
Coherus Oncology (CHRS) and Zumutor Biologics announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a NK checkpoint anti-LLT1 monoclonal antibody in combination ...
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008,...
Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust immuno-oncology pipeline, with LOQTORZI driving commercial growth and serving as a backbone for novel combinations. Tagmokitug and casdozokitug are advancing in multiple indications, with key data and global deals expected over the next 6–18 months.
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Transcript: AGM 2026
The meeting approved director elections, auditor ratification, executive compensation, and an increase in equity plan shares. The proposal to reduce stock option exercise prices was adjourned for further voting, with the Q&A session postponed until all business is concluded.
Coherus Oncology reports Q1 EPS (28c), consensus (26c)
Reports Q1 revenue $12.31M, consensus $14.34M. “We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination wit...
Coherus Oncology Earnings Call Transcript: Q1 2026
Q1 2026 saw 61% year-over-year LOQTORZI sales growth, robust new patient starts, and strong pipeline progress despite seasonal headwinds. The company raised $54 million, maintains $167 million in cash, and expects continued double-digit quarterly demand growth for LOQTORZI.
Coherus Oncology Earnings release: Q1 2026
Coherus Oncology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Coherus Oncology Quarterly report: Q1 2026
Coherus Oncology has published its Q1 2026 quarterly earnings report on May 11, 2026.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projectio...
Guggenheim starts Coherus with Buy on anti-tumor potential
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target Coherus recently completed a transformation from a biosimilars platform to a pure-play immuno-oncology c...
Coherus Oncology initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monda...
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026
The company has transformed into a focused oncology innovator, advancing LOQTORZI, tagmokitug, and casdozokitug across multiple cancer indications. Strong sales growth, strategic collaborations, and promising clinical data position it for significant market expansion and pivotal trial decisions in 2026.
Coherus Oncology reports Q4 EPS (34c), consensus (31c)
Reports Q4 revenue $12.75M, consensus $14.09M. “We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative ...
Coherus Oncology Earnings Call Transcript: Q4 2025
Transformation to a focused oncology company drove LOQTORZI sales up 113% year-over-year, with debt reduced by over 90%. Multiple clinical trials for tagmokitug and casdozokitug are underway, with key data readouts expected from mid-2026.
Coherus Oncology Annual report: Q4 2025
Coherus Oncology has published its Q4 2025 annual report on March 9, 2026.
Coherus Oncology Earnings release: Q4 2025
Coherus Oncology released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172...
Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Management highlighted a successful transformation to oncology, major debt reduction, and strong commercial momentum for LOQTORZI. Pipeline assets tagmokitug and casdozokitug show promising clinical data and broad partnering opportunities, with key data readouts expected mid-year.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after mark...